Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Supportive and palliative care

5414 - Prevalence and recent time trend in aggressiveness of cancer care near the end of life: an expanded assessment in a cohort study


09 Sep 2017


Supportive and palliative care


Diogo Martins Branco


Annals of Oncology (2017) 28 (suppl_5): v497-v501. 10.1093/annonc/mdx382


D. Martins Branco1, S. Lopes2, R. Canario1, J. Freire3, G. Sousa4, N. Lunet5, B. Gomes6

Author affiliations

  • 1 King’s College, Cicely Saunders Institute, Department of Palliative Care, Policy and Rehabilitation, SE5 9PJ - London/GB
  • 2 Escola Nacional De Saúde Pública E Centro De Investigação Em Saúde Pública, Universidade NOVA de Lisboa, Lisbon/PT
  • 3 Medical Oncology Department, Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P.E. (IPOLFG EPE), Lisbon/PT
  • 4 Medical Oncology Department, Instituto Português de Oncologia de Coimbra, Francisco Gentil, E.P.E. (IPOLFG EPE), Coimbra/PT
  • 5 Institute Of Public Health, University of Porto, Oporto/PT
  • 6 Faculty Of Medicine, University of Coimbra, Coimbra/PT


Abstract 5414


There is growing concern in society about aggressiveness of cancer care near the end of life (ACCEoL), mainly in metastatic disease. This study aims to determine prevalence and recent time trend of ACCEoL of adult cancer patients in a European country, comparing metastatic with others.


Cohort study of adults with ICD-9-CM diagnosis of cancer, who died in public hospitals in mainland Portugal (Jan’10 - Dec’15), identified from the Hospital Morbidity database (HMD). HMD provided data on primary cancer site, presence of metastatic disease and primary outcome: a composite ACCEoL indicator aggregating presence of 1 of 14 individual indicators in the last 30 days of life or chemo, immunotherapy or biological agents in the last 14 days of life (expansion of Earle et al 2004 framework). We calculated the prevalence of composite and individual indicators and examined time trends (chi2 test for trend) for the whole cohort, in metastatic disease and for main primary cancers. We considered clinically meaningful > 5% change.


92,155 patients were included (median age 73 yo, IQR 62-81; 61.9% male; 53.0% metastatic). The prevalence of the ACCEoL was 71.1%, 69.9% in metastatic patients vs. 72.6% in others (p  5% change.


Surprisingly, we found unchanged trends of high ACCEoL among adult patients and no clinically meaningful difference for metastatic disease group. A lack of integrated palliative care, even with growing resources in the timeframe analysed, suggest that these have not been enough to reduce ACCEoL. The reduced ACCEoL in patients who died with slow progressive cancers (e.g. breast) suggests that better knowledge of disease trajectories can contribute towards reducing ACCEoL.

Clinical trial identification


Legal entity responsible for the study



Calouste Gulbenkian Foundation, Liga Portuguesa Contra o Cancro - Núcleo Regional do Sul


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.